The First New Class of ADHD Drug in Decades Just Got the Green Light
The FDA just approved the first entirely new class of ADHD medication in decades. Centanafadine hits all three neurotransmitters, not just the usual two, and that serotonin twist could reshape treatment for millions of patients.
For roughly 60 years, treating ADHD has meant choosing between two basic levers in the brain: norepinephrine and dopamine. Stimulants like Adderall and Vyvanse crank up both. Non-stimulants like Strattera (atomoxetine) mostly pull the norepinephrine lever alone. Pick your flavor, manage the side effects, hope it works.
Now there's a third option, and it pulls a lever nobody's touched before in ADHD.
On July 24, the FDA approved Simtriyo (centanafadine), a once-daily pill that blocks the reuptake of not two, but three neurotransmitters: norepinephrine, dopamine, and serotonin. It's the first drug in an entirely new pharmacological class (norepinephrine-dopamine-serotonin reuptake inhibitor, or NDSRI) approved for ADHD. The label covers adults and kids ages six and up weighing at least 20 kg (about 44 pounds).
That serotonin piece? It's a bigger deal than it sounds.
Why Serotonin Changes the Game
Think of your brain's attention system like a three-legged stool. Norepinephrine handles alertness. Dopamine handles motivation and reward. Serotonin helps regulate mood, anxiety, and emotional control. Traditional ADHD meds prop up two legs and leave the third wobbly.
Centanafadine props up all three, with the strongest effect on norepinephrine. In lab studies, the drug's potency ratio is roughly 6:1 for norepinephrine over dopamine and 14:1 over serotonin. So it's not blasting all three equally; it's more like a norepinephrine-heavy cocktail with meaningful dopamine and serotonin kickers.
Why does that matter clinically? ADHD rarely travels alone. Anxiety and emotional dysregulation are extremely common co-travelers. A Phase 3b trial in adults with ADHD plus comorbid anxiety showed centanafadine improved ADHD symptoms significantly (treatment difference of -5.87 points on the primary scale vs. placebo, p < 0.0001) and also nudged anxiety scores in the right direction. That dual benefit is hard to find in existing ADHD meds.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Evidence Behind the Approval
The FDA's green light rests on four randomized, double-blind, placebo-controlled Phase 3 trials spanning children, adolescents, and adults. The adult data is the most detailed.
In two pivotal trials pooling 859 adults, patients on centanafadine at 200 mg and 400 mg daily saw their ADHD symptom scores drop by 12.1 and 12.5 points, respectively, compared to 8.1 for placebo. Both doses hit statistical significance (p = 0.002 and p = 0.0009). The global severity measure confirmed the findings: patients genuinely got better, not just on paper.
A 52-week open-label extension study showed the improvements stuck around. Patients saw their symptom scores improve by 49 to 57 percent over the year, with no new safety red flags popping up. Only 1.8% of participants experienced a serious adverse event, and investigators judged none of them related to the drug.
On the safety side, the most common complaints were familiar to anyone who's taken an ADHD med: decreased appetite, nausea, headache, and insomnia. In kids, rash joined the list. Most side effects were mild to moderate.
Better Than Stimulants? Not Exactly.
This is where the story gets nuanced. Indirect comparisons (not head-to-head trials, but statistical matchups called MAICs) suggest centanafadine is slightly less effective than lisdexamfetamine (Vyvanse) and possibly a touch behind methylphenidate. It lands roughly on par with atomoxetine and viloxazine.
But the tolerability story flips that script. Compared to methylphenidate, centanafadine showed significantly lower rates of dry mouth, insomnia, decreased appetite, anxiety, palpitations, and jitteriness. The safety advantage was consistent across analyses, even when the efficacy comparison wobbled.
In other words: it's probably not your best bet if raw symptom reduction is all you care about. But for patients who can't tolerate stimulants, worry about abuse, or struggle with anxiety alongside their ADHD, centanafadine fills a real gap.
The $15 Billion Question
The global ADHD therapeutics market sits somewhere in the range of $16 to $27 billion in 2026, depending on which analyst you ask. Stimulants still dominate, capturing roughly 90% of prescriptions. Non-stimulants are the smaller but faster-growing slice.
Otsuka Pharmaceutical, which acquired centanafadine through its 2017 purchase of Neurovance, is targeting peak sales above 100 billion yen (roughly $610 million). Jefferies analysts called it Otsuka's "next major CNS launch" and a potential blockbuster, noting that it's more likely to expand the non-stimulant pie than simply steal slices from existing players like Qelbree or generic Strattera.
The DEA Wildcard
There's one massive variable still in play. The FDA classified centanafadine as a CNS stimulant on the label, which means it needs DEA scheduling before Otsuka can start selling it. The formal approval date, legally speaking, is whenever the DEA publishes its scheduling decision in the Federal Register.
If centanafadine lands in Schedule II (alongside Adderall and Vyvanse), it faces the same prescribing restrictions and refill hassles that make stimulants a pain for patients and doctors. That would blunt one of its biggest potential advantages.
A less restrictive classification, say Schedule III or IV, would be a commercial gift. It would make the drug easier to prescribe, especially in primary care and the booming telehealth ADHD space. Jefferies flagged scheduling as "critical to commercial potential," and they're not wrong. The difference between Schedule II and Schedule IV could be the difference between a solid performer and a genuine blockbuster.
What This Means for Patients
Centanafadine's journey from a small biotech called DOV Pharmaceutical to an FDA-approved drug took roughly two decades. It changed hands three times. It's the kind of slow, winding path that rarely makes headlines but quietly reshapes how millions of people manage a condition that affects their work, relationships, and daily life.
For the estimated 15.5 million adults and millions more children living with ADHD in the U.S., the arrival of a genuinely new drug class is significant. Not because it's a miracle cure (it isn't), but because ADHD treatment has been stuck in the same pharmacological box for a very long time. Simtriyo doesn't replace what's already there. It adds a third option where there were only two, and for plenty of patients, that third option is exactly what they've been waiting for.
Clinical & Regulatory4 min read
Moderna's Flu Shot Just Cleared Its Biggest Hurdle Yet
Moderna's mRNA flu vaccine just got a unanimous thumbs-up from the FDA's advisory committee. If approved by August 5, it would be the first mRNA flu shot ever licensed in the U.S., opening a multibillion-dollar market that could redefine Moderna's future beyond COVID.
